Aperion Biologics, Inc. announced the enrollment and implantation of the first patients in the Company’s clinical trial of its Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) Device for the treatment of ligament injuries of the knee. The primary objective of the multicenter study is to provide additional evidence of the safety and performance of Z-Lig in the reconstruction of patients’ knees with primary ACL ruptures. Seven sites in Europe and one site in South Africa are participating in this clinical trial. Dr. Willem van der Merwe of the Sports Science Orthopaedic Clinic in Cape Town, South Africa said, “We are pleased to be part of this cutting-edge study. Graft options are limited for ligament reconstruction procedures and Z-Lig could prove to be a tissue alternative which would enhance the world of ACL reconstruction surgeries.” The study results will be used to support regulatory approvals and clinical acceptance of the Z-Lig ACLR device in select markets outside of the United States.